GTHX Financial Statements From 2010 to 2024

GTHX Stock  USD 4.43  0.04  0.89%   
G1 Therapeutics financial statements provide useful quarterly and yearly information to potential G1 Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on G1 Therapeutics financial statements helps investors assess G1 Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting G1 Therapeutics' valuation are summarized below:
We have found one hundred twenty available fundamental measures for G1 Therapeutics, which can be analyzed and compared to other ratios and to its peers in the sector. All investors should make sure to confirm all of G1 Therapeutics latest market performance against the performance between 2010 and 2024 to make sure the company can sustain itself this quarter and beyond.
Check G1 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GTHX main balance sheet or income statement drivers, such as Depreciation And Amortization of 291.2 K, Interest Expense of 10.5 M or Selling General Administrative of 46.9 M, as well as many exotic indicators such as Price To Sales Ratio of 1.82, Dividend Yield of 0.0 or Operating Cycle of 1.1 K. GTHX financial statements analysis is a perfect complement when working with G1 Therapeutics Valuation or Volatility modules.
  
This module can also supplement various G1 Therapeutics Technical models . Check out the analysis of G1 Therapeutics Correlation against competitors.
For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.

G1 Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets179.2 M121.5 M121.6 M
Slightly volatile
Other Current Liabilities12.5 M23.8 M8.4 M
Slightly volatile
Total Current Liabilities18.5 M29.7 M12.5 M
Slightly volatile
Property Plant And Equipment Net5.4 M6.4 M3.7 M
Slightly volatile
Accounts Payable3.6 MM2.5 M
Slightly volatile
Cash30.7 M32.3 M94.5 M
Slightly volatile
Non Current Assets Total5.9 M6.6 MM
Slightly volatile
Cash And Short Term Investments161.9 M82.2 M109.9 M
Slightly volatile
Common Stock Shares Outstanding33.7 M51.7 M23 M
Slightly volatile
Other Current Assets4.6 M7.6 M3.1 M
Slightly volatile
Total Liabilities47.2 M86.2 M31.8 M
Slightly volatile
Total Current Assets173.3 M114.9 M117.6 M
Slightly volatile
Common Stock3.3 K5.8 K2.3 K
Slightly volatile
Property Plant Equipment2.7 M2.3 M1.8 M
Slightly volatile
Common Stock Total Equity3.3 K5.8 K2.3 K
Slightly volatile
Property Plant And Equipment Gross6.7 M8.7 M4.2 M
Slightly volatile
Other Liabilities595.9 K1.1 M431.1 K
Slightly volatile
Capital Surpluse647.2 M920.9 M443.7 M
Slightly volatile
Net Invested Capital155 M86.9 M144.3 M
Slightly volatile
Net Working Capital153.1 M85.2 M142.9 M
Slightly volatile
Capital Stock4.8 K5.8 K4.2 K
Slightly volatile
Short and Long Term Debt Total57.6 M57.2 M27.4 M
Slightly volatile
Capital Lease Obligations5.9 M4.3 MM
Slightly volatile
Short Term Debt1.2 M1.3 M1.9 M
Pretty Stable
Current Deferred Revenue651 K620 K261.1 K
Slightly volatile
Net Receivables8.2 M12.7 M2.7 M
Slightly volatile
Long Term Debt Total63.1 M88.6 M34.8 M
Slightly volatile

G1 Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative46.9 M79.5 M32.3 M
Slightly volatile
Other Operating Expenses105.4 M122 M73 M
Slightly volatile
Research Development58.6 M43.7 M40.8 M
Slightly volatile
Total Operating Expenses103.5 M114.8 M70.3 M
Slightly volatile
Preferred Stock And Other Adjustments3.8 M4.3 M4.7 M
Slightly volatile
Reconciled Depreciation428.5 K526 K251.9 K
Slightly volatile
Tax Provision1.9 M2.7 M1.5 M
Slightly volatile
Interest Income2.5 M2.4 M1.1 M
Slightly volatile

G1 Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock83.4 M60.4 M55.1 M
Slightly volatile
Stock Based Compensation11.9 M14.5 MM
Slightly volatile
Depreciation312.5 K513 K214.8 K
Slightly volatile
End Period Cash Flow30.7 M32.3 M94.6 M
Slightly volatile
Change To Netincome12.3 M24.7 M9.2 M
Slightly volatile
Begin Period Cash Flow163.9 M94.7 M101.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.821.912351.5005
Pretty Stable
Operating Cycle1.1 K687786
Slightly volatile
Days Of Payables Outstanding1922031.4 K
Very volatile
Inventory Turnover0.510.57830.5526
Slightly volatile
Ebt Per Ebit1.161.13471.041
Pretty Stable
Payables Turnover1.711.80246.0579
Slightly volatile
Cash Per Share1.511.58933.9754
Pretty Stable
Quick Ratio3.033.193810.1443
Slightly volatile
Dividend Paid And Capex Coverage Ratio240229141
Slightly volatile
Net Income Per E B T0.821.06951.0189
Slightly volatile
Cash Ratio1.031.08639.7407
Slightly volatile
Days Of Inventory Outstanding756631700
Slightly volatile
Days Of Sales Outstanding40.5856.122917.5071
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.90.9907
Slightly volatile
Current Ratio3.673.868210.4121
Pretty Stable
Fixed Asset Turnover13.5712.92477.461
Very volatile
Capital Expenditure Coverage Ratio240229141
Slightly volatile
Debt Ratio0.230.43470.1326
Slightly volatile
Price Sales Ratio1.821.912351.5005
Pretty Stable
Receivables Turnover6.186.5036142
Slightly volatile
Asset Turnover0.710.67890.2775
Slightly volatile

GTHX Fundamental Market Drivers

Cash And Short Term Investments82.2 M

GTHX Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About G1 Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include G1 Therapeutics income statement, its balance sheet, and the statement of cash flows. G1 Therapeutics investors use historical funamental indicators, such as G1 Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although G1 Therapeutics investors may use each financial statement separately, they are all related. The changes in G1 Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on G1 Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on G1 Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in G1 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue620 K651 K
Total Revenue82.5 M86.6 M
Cost Of Revenue7.2 M6.8 M
Ebit Per Revenue(0.48)(0.50)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards G1 Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, G1 Therapeutics' short interest history, or implied volatility extrapolated from G1 Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether G1 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of G1 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of G1 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on G1 Therapeutics Stock:
Check out the analysis of G1 Therapeutics Correlation against competitors.
For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.
Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for GTHX Stock analysis

When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.